MRD testing by flow cytometry according to the ACS guidelines: Dos and Don’ts
Speaker
Dr Mary Sartor, BSc, MSc, PhD.
Retired principal flow cytometry scientist at Westmead Hospital, Sydney Australia.
Objectives of Lecture
This webinar is to introduce the ACS Guidelines for Minimal Residual Disease Testing by flow cytometry, which covers phases of pre-analytical, analytical, post analytical, then with case studies of ALL and AML.
Abstract of Lecture
Minimal residual disease (MRD) describes disease that can be diagnosed by methodologies other than conventional morphology. Detection and monitoring of MRD is becoming the standard of care and is providing a surrogate endpoint of survival for an increasing number of haematopoietic neoplasms. Despite advances in molecular techniques, flow cytometry remains advantageous due to broader applicability and accessibility. This talk will focus on the ACS Clinical Guidelines for MRD testing in leukemia. The guidelines are a consensus document that summarises the many international clinical guidelines published on MRD assessment by flow cytometry and its intended use is to assist clinical laboratories with setting up assays as well as serving as an audit curriculum for internal and external assessment.
We hope you have enjoyed the webinar and gained new insights!
May we request your time for a survey?
